Floatz logo

Gefetinib

Brain Metastases

Alpha Biopharma (Jiangsu) Co., Ltd.Phase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
73/ 100

Competitive context

103 Active assets in the Brain Metastases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Gefetinib is also rated in:

central nervous system neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative ·
71 / 100
View asset →
lung adenocarcinoma in situDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →